CAS 2242470-43-3

Fórmula: C23H20N2O2

InChI: InChI=1S/C23H20N2O2/c26-22-20-16-5-6-17(19-12-18(16)19)21(20)23(27)25(22)15-3-1-13(2-4-15)11-14-7-9-24-10-8-14/h1-10,16-21H,11-12H2

Clave InChI: LOXMLWHUIONWMI-UHFFFAOYSA-N

SMILES: C1C2C1C3C=CC2C4C3C(=O)N(C4=O)C5=CC=C(C=C5)CC6=CC=NC=C6

DCZ0415

CAS: 2242470-43-3

DCZ0415: Potent TRIP13 inhibitor; combats myeloma in vitro, in vivo, and in drug-resistant patients; hinders DNA repair and NF-κB activity.

Fórmula: C₂₃H₂₀N₂O₂

Pureza: 99.34% - 99.95%

Forma y color: White Solid

Peso molecular: 356.4171

Ref: TM-T10981

2-(4-(Pyridin-4-ylmethyl)phenyl)-4,4a,5,5a,6,6a-hexahydro-4,6-ethenocyclopropa[f]isoindole-1,3(2H,3aH)-dione

CAS: 2242470-43-3

Fórmula: C₂₃H₂₀N₂O₂

Pureza: 98%

Peso molecular: 356.4171

Ref: IN-DA01V2NS

DCZ0415

CAS: 2242470-43-3

DCZ0415

Fórmula: C₂₃H₂₀N₂O₂

Pureza: ≥98%

Peso molecular: 356.42

Ref: 54-BUP02433

DCZ0415

CAS: 2242470-43-3

DCZ0415 is a histone deacetylase (HDAC) inhibitor. It is used for the treatment of cancer by inducing cell differentiation and inhibiting tumor growth. DCZ0415 has been shown to be effective in a number of animal models, including those with prostate cancer, breast cancer, and colon cancer. This drug has also been shown to be effective in treating malignant cancers in humans, such as lung and pancreatic cancers. DCZ0415 inhibits HDAC activity at the transcriptional level and has been shown to have anti-inflammatory effects.

Fórmula: C₂₃H₂₀N₂O₂

Pureza: Min. 95%

Peso molecular: 356.4 g/mol

Ref: 3D-SPD47043